Immunotherapy, particularly combining checkpoint inhibitors with targeted drugs, boosts responses in resistant cases like lung cancer and Hodgkin lymphoma. Trials show promise in overcoming tumor resistance.
JAK inhibitors remodel the immune system for better checkpoint inhibitor responsiveness. Combining therapies might tackle tumor resistance pathways, allowing immune cells to identify and eradicate cancer cells effectively.
Collection
[
|
...
]